Drug intelligence / Profile preview

BIO-205

Development stage: Unknown
Lead developer: BioIntervene
Modality: Small Molecules

Overview

BIO-205 is a lead drug candidate developed by BioIntervene, a biopharmaceutical company. It functions as a selective A3 adenosine receptor (A3AR) agonist. The company is advancing BIO-205 through human proof-of-concept studies for the treatment of neuropathic pain. The technology underpinning BIO-205 was licensed from Saint Louis University and the NIH, and its development is supported by a $30 million Series A financing round led by MPM Capital.

Targets

ADORA3 (Adenosine A3 receptor)

Beyond the preview

Go deeper on BIO-205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIO-205.

Explore the full profile